Literature DB >> 10504359

Pelvic osteotomies for the treatment of hip dysplasia in children and young adults.

B L Gillingham1, A A Sanchez, D R Wenger.   

Abstract

Persistent acetabular dysplasia is a well-known cause of premature hip osteoarthritis. In the dysplastic hip, point loading occurs at the edge of the steep, shallow acetabulum. Pelvic osteotomies reduce this load by increasing the contact area, relaxing the capsule and muscles about the hip, improving the moment arm of the hip, and normalizing the forces of weight bearing. The orthopaedic surgeon can choose from among a variety of pelvic osteotomies (e.g., redirectional, reshaping, and salvage) for the purpose of restoring normal anatomy and biomechanical forces across the hip joint. Treatment of residual dysplasia is based on the patient's age and the presence or absence of congruent hip reduction. A Salter or Pemberton procedure is generally appropriate for a child between the ages of 2 and 10. A triple innominate osteotomy can be considered for the older child or adolescent in whom the triradiate cartilage remains open. After triradiate closure, the Ganz periacetabular osteotomy can be considered in addition to the triple innominate osteotomy.

Entities:  

Mesh:

Year:  1999        PMID: 10504359     DOI: 10.5435/00124635-199909000-00005

Source DB:  PubMed          Journal:  J Am Acad Orthop Surg        ISSN: 1067-151X            Impact factor:   3.020


  18 in total

Review 1.  Developmental dysplasia of the hip: What has changed in the last 20 years?

Authors:  Pavel Kotlarsky; Reuben Haber; Victor Bialik; Mark Eidelman
Journal:  World J Orthop       Date:  2015-12-18

2.  Bernese-type triple pelvic osteotomy through a single incision in children over five years: a retrospective study of twenty eight cases.

Authors:  YiQiang Li; HongWen Xu; Theddy Slongo; QingHe Zhou; Yuanzhong Liu; WeiDong Chen; JingChun Li; Federico Canavese
Journal:  Int Orthop       Date:  2018-04-23       Impact factor: 3.075

3.  Management of sequelae of septic arthritis of hip.

Authors:  Kl Jagadishwer Rao; Durga Prasad; Kantilal Jain
Journal:  Indian J Orthop       Date:  2007-10       Impact factor: 1.251

4.  Radiographic outcome of children older than twenty-four months with developmental dysplasia of the hip treated by closed reduction and spica cast immobilization in human position: a review of fifty-one hips.

Authors:  YiQiang Li; YueMing Guo; XianTao Shen; Hang Liu; HaiBo Mei; HongWen Xu; Federico Canavese
Journal:  Int Orthop       Date:  2019-04-12       Impact factor: 3.075

5.  Returning to sports after periacetabular osteotomy for developmental dysplasia of the hip.

Authors:  Steven R Tippett
Journal:  N Am J Sports Phys Ther       Date:  2006-02

Review 6.  Current knowledge and importance of dGEMRIC techniques in diagnosis of hip joint diseases.

Authors:  Christoph Zilkens; Carl Johann Tiderius; Rüdiger Krauspe; Bernd Bittersohl
Journal:  Skeletal Radiol       Date:  2015-04-26       Impact factor: 2.199

7.  The effect of Dega acetabuloplasty and Salter innominate osteotomy on acetabular remodeling monitored by the acetabular index in walking DDH patients between 2 and 6 years of age: short- to middle-term follow-up.

Authors:  Mohamed El-Sayed; Tarek Ahmed; Sameh Fathy; Hosam Zyton
Journal:  J Child Orthop       Date:  2012-11-28       Impact factor: 1.548

8.  [The natural history of developmental dysplasia of the hip. A meta-analysis of the published literature].

Authors:  J Ziegler; F Thielemann; C Mayer-Athenstaedt; K-P Günther
Journal:  Orthopade       Date:  2008-06       Impact factor: 1.087

9.  Blood Transfusion Incidence, Risk Factors, and Associated Complications in Surgical Treatment of Hip Dysplasia.

Authors:  Brandon A Sherrod; Dustin K Baker; Shawn R Gilbert
Journal:  J Pediatr Orthop       Date:  2018-04       Impact factor: 2.324

10.  Radiographic and clinical analysis of pelvic triple osteotomy for adult hip dysplasia.

Authors:  Antony R Liddell; Gareth Prosser
Journal:  J Orthop Surg Res       Date:  2013-06-07       Impact factor: 2.359

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.